BioCentury
ARTICLE | Clinical News

Bridion sugammadex regulatory update

December 21, 2015 8:00 AM UTC

FDA approved Bridion sugammadex from Merck to reverse the effects of neuromuscular blockade induced by muscle relaxants rocuronium or vecuronium in adults undergoing surgery. Merck plans to launch the cyclodextrin derivative next month, at which time the pharma will disclose the drug’s price. ...